Daniel Abbott, MD
University of Texas M. D. Anderson Cancer Center |
Neoadjuvant chemoradiation versus surgery first for resectable pancreatic head adenocarcinoma: An economic and outcome analysis. |
Amanda Arrington, MD
City of Hope National Medical Center |
Laparoscopic gastrectomy for gastric adenocarcinoma: A single institution’s experience and oncologic outcomes of 65 consecutive patients. |
Genevieve Boland, MD, PhD
University of Texas M. D. Anderson Cancer Center |
Association of NCCN guideline adherence with improved survival in high-risk stage II and stage III colon cancer. |
Terence Chua, BSc Med (Hons) MB BS
University of New South Wales |
Early and long-term outcome data on 2,298 patients with pseudomyxoma peritonei of appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. |
Sebastian De La Fuente, MD
H. Lee Moffitt Cancer Center & Research Institute |
Safety and oncologic outcomes of robotic-assisted esophagogastrectomy. |
Mary Guye, MD
City of Hope National Medical Center |
The prognostic significance of extra-intestinal tumor location for primary nonmetastatic gastrointestinal stromal tumors. |
Danielle Hari, MD
John Wayne Cancer Institute at St. Johns Health Center |
A 21-year analysis of lymph node trends in colon cancer: Do quality measures really matter? |
Alex Haynes, MD, MPH
University of Texas M. D. Anderson Cancer Center |
Association between delays in adjuvant chemotherapy for stage III colon cancer and increased mortality. |
Melissa Labonte
University of Southern California Norris Comprehensive Cancer Center |
Use of EGF A61G polymorphism to predict overall survival in a phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma (SWOG 0205). |
Anna Leung, MD
John Wayne Cancer Institute at St. Johns Health Center |
Changing national trends and survival in stage IV gastric cancer |
Lee McGhan, MB, BCh
Mayo Clinic |
Validation of a gastric cancer nomogram using a U.S. cancer registry. |
Abigail Milby, MD
Department of Radiation Oncology, Hospital of the University of Pennsylvania |
Long-term cardiopulmonary mortality after radiation for locally advanced esophageal cancer. |
Manali Patel, MD
Stanford University Medical Center |
Seventh edition (2010) of gastric adenocarcinoma AJCC staging system: Is there room for improvement? |
Jose Pimiento, MD
H. Lee Moffitt Cancer Center & Research Institute |
Low 18f-fluorodeoxyglucose uptake on positron emission tomography as a prognostic factor for stage I and II pancreatic cancer. |
Maria Russell, MD
University of Texas M. D. Anderson Cancer Center |
Lymph node metastasis in patients with early pathologic T-stage rectal cancers: What does local excision leave behind? |
Heath Skinner, MD, PhD
University of Texas M. D. Anderson Cancer Center |
Phase I trial of radiotherapy with concurrent bevacizumab, erlotinib, and capecitabine for locally advanced pancreatic cancer (LAPC). |
Akihiro Suzuki, MD
University of Texas M. D. Anderson Cancer Center |
Nomograms for prognostication of patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. |
Takashi Taketa, MD
The University of Texas, MD Anderson Cancer Center |
Outcome of trimodality-eligible esophagogastric cancer (EC) patients who declined surgery after preoperative chemoradiation. |
Ryan Thomas, MD
The University of Texas M. D. Anderson Cancer Center |
Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. |
George Van Buren, MD
University of Pittsburgh |
Phase II trial of fixed-dose rate gemcitabine, bevacizumab, and concurrent 30 gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. |